Kodiak Sciences begins subject treatment in DME therapy trial

Kodiak Sciences begins subject treatment in DME therapy trial

Source: 
Clinical Trials Arena
snippet: 

Biopharmaceutical company Kodiak Sciences has treated the first participant in the Phase I clinical trial of its investigational bispecific antibody biopolymer conjugate (ABC), KSI-501, for diabetic macular oedema (DME).